检查点抑制剂肺炎——真实世界发病率及风险 - Suppr

Checkpoint Inhibitor Pneumonitis - Real-World Incidence and Risk.

作者信息

Tay Rebecca Y, Califano Raffaele

机构信息

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.

出版信息

J Thorac Oncol. 2018 Dec;13(12):1812-1814. doi: 10.1016/j.jtho.2018.10.007.

DOI:10.1016/j.jtho.2018.10.007

PMID:30467044

Abstract

摘要

相似文献

Checkpoint Inhibitor Pneumonitis - Real-World Incidence and Risk.检查点抑制剂肺炎——真实世界发病率及风险

J Thorac Oncol. 2018 Dec;13(12):1812-1814. doi: 10.1016/j.jtho.2018.10.007.

Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?检查点抑制剂肺炎：临床严重程度是否抵消了其益处？

J Thorac Oncol. 2019 Mar;14(3):332-335. doi: 10.1016/j.jtho.2018.12.017.

Comment on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.评论：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌患者的肺炎：153个队列15713例患者的荟萃分析：非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂相关性肺炎的发病率及危险因素荟萃分析

Lung Cancer. 2019 Jan;127:167. doi: 10.1016/j.lungcan.2018.09.018. Epub 2018 Sep 24.

Reply to the comments on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.对以下评论的回复：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌患者的肺炎：对153个队列中15713例患者的荟萃分析——非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂相关性肺炎的发病率及危险因素的荟萃分析

Lung Cancer. 2019 Jan;127:168. doi: 10.1016/j.lungcan.2018.11.005. Epub 2018 Nov 8.

Risk of Pneumonitis with the Use of Different Immune Checkpoint Inhibitors in a Mexican Population.墨西哥人群使用不同免疫检查点抑制剂的间质性肺病风险。

Oncology. 2019;96(5):268-272. doi: 10.1159/000497405. Epub 2019 Mar 12.

Immune Checkpoint Inhibitor-related Pneumonitis. Incidence, Risk Factors, and Clinical and Radiographic Features.免疫检查点抑制剂相关肺炎。发病率、危险因素以及临床和影像学特征。

Am J Respir Crit Care Med. 2018 Oct 1;198(7):951-953. doi: 10.1164/rccm.201803-0525RR.

Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.晚期非小细胞肺癌患者接受表皮生长因子受体酪氨酸激酶抑制剂治疗后的肺炎：153 个队列 15713 例患者的荟萃分析：非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂性肺炎的发生率和危险因素的荟萃分析。

Lung Cancer. 2018 Sep;123:60-69. doi: 10.1016/j.lungcan.2018.06.032. Epub 2018 Jun 30.

High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.纳武利尤单抗致肺炎的高发生率和早发性：4 例病例报告及文献复习。

BMC Pulm Med. 2018 Jan 30;18(1):23. doi: 10.1186/s12890-018-0592-x.

Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung Cancer.肺癌免疫治疗后发生肺炎的患者生存率较低。

Clin Lung Cancer. 2020 May;21(3):e169-e170. doi: 10.1016/j.cllc.2019.10.009. Epub 2019 Nov 6.

Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.尼伏鲁单抗停药后反复发生的免疫性肺炎及癌胚抗原水平的时间变化：1 例 58 岁女性非小细胞肺癌病例报告

Chemotherapy. 2018;63(5):272-277. doi: 10.1159/000494841. Epub 2018 Dec 20.

引用本文的文献

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME).RRx-001 联合纳武利尤单抗治疗晚期转移性癌症患者的 1 期初步研究（PRIMETIME）。

Front Immunol. 2023 Mar 7;14:1104753. doi: 10.3389/fimmu.2023.1104753. eCollection 2023.

A Novel Workflow to Create a Checkpoint Inhibitor Pneumonitis Patient Registry.创建检查点抑制剂肺炎患者登记处的新型工作流程。

Cureus. 2023 Feb 6;15(2):e34683. doi: 10.7759/cureus.34683. eCollection 2023 Feb.

Immunotherapy Assessment: A New Paradigm for Radiologists.免疫疗法评估：放射科医生的新范例

Diagnostics (Basel). 2023 Jan 13;13(2):302. doi: 10.3390/diagnostics13020302.

Pulmonary Lymphangitis Poses a Major Challenge for Radiologists in an Oncological Setting during the COVID-19 Pandemic.在新冠疫情期间，肺部淋巴管炎给肿瘤学领域的放射科医生带来了重大挑战。

J Pers Med. 2022 Apr 12;12(4):624. doi: 10.3390/jpm12040624.

Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications.免疫检查点抑制剂与放疗相关肺炎：一种确定真实世界发病率、严重程度、管理及资源影响的信息学方法。

Front Med (Lausanne). 2021 Nov 1;8:764563. doi: 10.3389/fmed.2021.764563. eCollection 2021.

Usefulness of Simple Original Interstitial Lung Abnormality Scores for Predicting Radiation Pneumonitis Requiring Steroidal Treatment After Definitive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer.简单原始间质性肺异常评分对预测局部晚期非小细胞肺癌患者根治性放疗后需要类固醇治疗的放射性肺炎的有用性。

Adv Radiat Oncol. 2020 Oct 31;6(1):100606. doi: 10.1016/j.adro.2020.10.019. eCollection 2021 Jan-Feb.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Checkpoint Inhibitor Pneumonitis - Real-World Incidence and Risk.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献